JP2024507638A - 性機能障害処置のための神経刺激性ステロイドの使用 - Google Patents

性機能障害処置のための神経刺激性ステロイドの使用 Download PDF

Info

Publication number
JP2024507638A
JP2024507638A JP2023540524A JP2023540524A JP2024507638A JP 2024507638 A JP2024507638 A JP 2024507638A JP 2023540524 A JP2023540524 A JP 2023540524A JP 2023540524 A JP2023540524 A JP 2023540524A JP 2024507638 A JP2024507638 A JP 2024507638A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
administered
sexual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023540524A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507638A5 (https=
Inventor
ビジャイベール ボンサパリー，
エリソン ストフ，
ハンダン グンドゥーズ－ブルース，
ライアン アーノルド，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics LLC
Original Assignee
Sage Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics LLC filed Critical Sage Therapeutics LLC
Publication of JP2024507638A publication Critical patent/JP2024507638A/ja
Publication of JP2024507638A5 publication Critical patent/JP2024507638A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2023540524A 2021-01-28 2022-01-27 性機能障害処置のための神経刺激性ステロイドの使用 Pending JP2024507638A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163142840P 2021-01-28 2021-01-28
US202163142833P 2021-01-28 2021-01-28
US63/142,833 2021-01-28
US63/142,840 2021-01-28
PCT/US2022/014075 WO2022165017A1 (en) 2021-01-28 2022-01-27 Use of neuroactive steroids for treatment of sexual dysfunction

Publications (2)

Publication Number Publication Date
JP2024507638A true JP2024507638A (ja) 2024-02-21
JP2024507638A5 JP2024507638A5 (https=) 2025-02-03

Family

ID=80787167

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023540524A Pending JP2024507638A (ja) 2021-01-28 2022-01-27 性機能障害処置のための神経刺激性ステロイドの使用

Country Status (9)

Country Link
US (1) US20240122945A1 (https=)
EP (1) EP4284382A1 (https=)
JP (1) JP2024507638A (https=)
KR (1) KR20230136599A (https=)
AU (1) AU2022214187A1 (https=)
CA (1) CA3206537A1 (https=)
IL (1) IL304080A (https=)
MX (1) MX2023008726A (https=)
WO (1) WO2022165017A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
PE20240780A1 (es) * 2021-07-28 2024-04-17 Sage Therapeutics Inc Formas cristalinas de un esteroide neuroactivo

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016535796A (ja) * 2013-11-11 2016-11-17 ユーシミクス・バイオサイエンス・インコーポレイテッドＥｕｔｈｙｍｉｃｓ Ｂｉｏｓｃｉｅｎｃｅ，Ｉｎｃ． 新規な方法
JP2017516793A (ja) * 2014-05-29 2017-06-22 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物、およびその使用
JP2019511488A (ja) * 2016-03-08 2019-04-25 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物、およびその使用
WO2019241442A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
WO2020180955A1 (en) * 2019-03-04 2020-09-10 Praxis Precision Medicines, Inc. Methods for the treatment of perimenopause and menopause

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200801081A1 (ru) * 2005-10-14 2008-10-30 Х. Лундбекк А/С Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016535796A (ja) * 2013-11-11 2016-11-17 ユーシミクス・バイオサイエンス・インコーポレイテッドＥｕｔｈｙｍｉｃｓ Ｂｉｏｓｃｉｅｎｃｅ，Ｉｎｃ． 新規な方法
JP2017516793A (ja) * 2014-05-29 2017-06-22 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物、およびその使用
JP2019511488A (ja) * 2016-03-08 2019-04-25 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物、およびその使用
WO2019241442A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
WO2020180955A1 (en) * 2019-03-04 2020-09-10 Praxis Precision Medicines, Inc. Methods for the treatment of perimenopause and menopause

Also Published As

Publication number Publication date
CA3206537A1 (en) 2022-08-04
IL304080A (en) 2023-08-01
MX2023008726A (es) 2023-12-14
KR20230136599A (ko) 2023-09-26
AU2022214187A1 (en) 2023-07-13
US20240122945A1 (en) 2024-04-18
AU2022214187A9 (en) 2024-05-23
EP4284382A1 (en) 2023-12-06
WO2022165017A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
JP2024507638A (ja) 性機能障害処置のための神経刺激性ステロイドの使用
WO2022177718A1 (en) Use of neuroactive steroid for treatment of sexual dysfunction
US8309535B2 (en) Compositions and methods to treat recurrent medical conditions
CN114712356A (zh) 用于治疗抑郁症的右美沙芬和安非他酮的组合
US10617660B2 (en) Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
JP2019515891A (ja) タンニン酸を含有する組成物及びその使用
KR20170068480A (ko) 다발성 경화증의 치료를 위한 시포니모드 및 라퀴니모드를 포함하는 조합물
JP2024516297A5 (https=)
JP2024503114A (ja) 神経精神疾患に対する抗うつ剤とデキストロメトルファンとの組み合わせ
TWI387452B (zh) 用於治療性功能障礙之方法
CN107949379A (zh) L‑4‑氯代犬尿氨酸的治疗用途
WO2001034172A2 (en) Methods and compositions for treating reward deficiency syndrome
JP2022552808A (ja) Ｇａｂａ－ａ受容体陽性アロステリック調節因子と、ｎｍｄａ拮抗薬、ｎｍｄａ陰性アロステリック調節因子、またはｎｍｄａ部分作動薬との組み合わせ
CN116847852A (zh) 神经活性类固醇治疗性功能障碍的用途
CZ2004739A3 (cs) Použití desoxypeganinu k ošetřování klinické deprese
WO2022235576A1 (en) Methods and compositions for treating depression
US20140148465A1 (en) Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine
US5455276A (en) Method for treating depression
JP7579027B2 (ja) セスキテルペンラクトン系化合物の視神経炎治療薬の製造における使用
WO2023023038A1 (en) Treatment compositions and methods
JP2008513430A (ja) 月経前症候群および月経前不快気分障害の処置のためのピンドロール
HK40100385A (zh) 用於神经精神病症的抗抑郁剂和右美沙芬的组合
AU2012307535A1 (en) Combinations comprising a S1P receptor modulator
SEINER et al. 15 Psychopharmacology and Neurotherapeutics

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251211

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260415